Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination SARS-CoV-2 variants

被引：0

作者：

Garcia-Perez, Javier ^{[1
,2
]}

Borobia, Alberto M. ^{[3
,4
]}

Perez-Olmeda, Mayte ^{[2
,5
]}

Portoles, Antonio ^{[7
]}

Castano, Luis ^{[7
]}

Campins-Arti, Magdalena ^{[8
]}

Bertran, Maria Jesus ^{[9
]}

Bermejo, Mercedes ^{[1
,2
]}

Arribas, Jose Ramon ^{[2
,4
]}

Lopez, Andrea ^{[5
]}

Ascaso-del-Rio, Ana ^{[6
]}

Arana-Arri, Eunate ^{[7
]}

Camps, Inmaculada Fuentes ^{[10
]}

Vilella, Anna ^{[9
]}

Cascajero, Almudena ^{[1
]}

Garcia-Morales, Maria Teresa ^{[11
]}

de la Osa, Maria Castillo ^{[5
]}

Ingidua, Carla Perez ^{[6
]}

Lora, David ^{[11
,12
,13
]}

Jimenez-Santana, Paloma ^{[1
]}

Pino-Rosa, Silvia ^{[5
]}

de la Camara, Agustin Gomez ^{[12
,13
]}

de la Torre-tarazona, Erick ^{[1
]}

Calonge, Esther ^{[2
]}

Cruces, Raquel ^{[1
]}

Belda-Iniesta, Cristo bal ^{[14
]}

Alcami, Jose ^{[1
,2
]}

Frias, Jesus ^{[3
]}

Carcas, Antonio J. ^{[3
]}

Diez-Fuertes, Francisco ^{[1
,2
]}

机构：

[1] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiologia, Unidad Inmunopatologi SIDA, Majadahonda 28222, Madrid, Spain

[2] Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Majadahonda 28222, Madrid, Spain

[3] Univ Autonoma Madrid, Hosp Univ La Paz, Fac Med, Dept Farmacologia & Terapeut,Serv Med Interna,IdiP, Madrid 28046, Spain

[4] Univ Autonoma Madrid, Hosp Univ La Paz, Fac Med, Serv Med Interna,Dept Med,IdiPAZ, Madrid 28046, Spain

[5] Inst Salud Carlos III ISCIII, Lab Serologia, Ctr Nacl Microbiologia, Majadahonda 28222, Madrid, Spain

[6] IdISSC, Serv Farmacologia Clin, Hosp Clin San Carlos, Madrid 28040, Spain

[7] Cruces Univ Hosp, Endo ERN, UPV EHU, CIBERDEM CIBERER,Biobizkaia, Baracaldo 48903, Vizcaya, Spain

[8] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Serv Med Prevent & Epidemiologia, Barcelona 08035, Spain

[9] Hosp Clin Barcelona, Serv Med Prevent & Epidemiologia, Barcelona 08036, Spain

[10] Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Farmacologia Clin, Unidad Soporte Invest Clin, Barcelona 08035, Spain

[11] Spanish Clin Res Network SCReN ISCIII, Madrid 28029, Spain

[12] Inst Invest Sanitaria Hosp Univ 12 octubre, Madrid 28041, Spain

[13] Univ Complutense Madrid, Fac Estudios Estadist, Madrid 28040, Spain

[14] Directorate Inst Salud Carlos III, Madrid 28029, Spain

来源：

ISCIENCE | 2024年 / 27卷 / 09期

关键词：

D O I：

10.1016/j.isci.2024.110728

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

引用

页数：13

共 50 条

[1] SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
Behrens, Georg M. N.
Cossmann, Anne
Stankov, Metodi V.
Nehlmeier, Inga
Kempf, Amy
Hoffmann, Markus
Poehlmann, Stefan
LANCET, 2021, 398 (10305): : 1041 - 1042
[2] Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection
Niesen, Michiel J. M.
Matson, Robert
Puranik, Arjun
O'Horo, John C.
Pawlowski, Colin
Vachon, Celine
Challener, Douglas
Virk, Abinash
Swift, Melanie
Speicher, Leigh
Gordon, Joel
Geyer, Holly
Lenehan, Patrick J.
Venkatakrishnan, A. J.
Soundararajan, Venky
Badley, Andrew
PNAS NEXUS, 2022, 1 (02):
[3] Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
Barocci, Simone
Orlandi, Chiara
Diotallevi, Aurora
Buffi, Gloria
Ceccarelli, Marcello
Vandini, Daniela
Carlotti, Eugenio
Galluzzi, Luca
Rocchi, Marco Bruno Luigi
Magnani, Mauro
Casabianca, Anna
VACCINES, 2022, 10 (04)
[4] Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
Zhang, Ruiqi
Leung, Ka-Yi
Liu, Danlei
Fan, Yujing
Lu, Lu
Chan, Pui-Chun
To, Kelvin Kai-Wang
Chen, Honglin
Yuen, Kwok-Yung
Chan, Kwok-Hung
Hung, Ivan Fan-Ngai
MSPHERE, 2022, 7 (02)
[5] INFLIXIMAB IS ASSOCIATED WITH ATTENUATED IMMUNOGENICITY TO BNT162B2 AND CHADOX1 NCOV-19 SARS-COV-2 VACCINES
Kennedy, Nicholas
Lin, Simeng
Goodhand, James
Powell, Nicholas
Ahmad, Tariq
GUT, 2021, 70 : A3 - A4
[6] Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Dimeglio, Chloe
Herin, Fabrice
Da-Silva, Isabelle
Jougla, Isabelle
Pradere, Claire
Porcheron, Marion
Martin-Blondel, Guillaume
Chapuy-Regaud, Sabine
Izopet, Jacques
CLINICAL INFECTIOUS DISEASES, 2022, 74 (07) : 1315 - 1316
[7] Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection
Alfaleh, Amjad
Alkattan, Abdullah
Alzaher, Abrar
Radwan, Nashwa
Mahmoud, Nagla
Alageel, Alaa
Alhabib, Dina
Alsalameen, Eman
Sagor, Khlood
Haji, Alhan
Alfaifi, Amal
Alabdulkareem, Khaled
Ibrahim, Mona
CLINICAL DRUG INVESTIGATION, 2022, 42 (10) : 799 - 806
[8] Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection
Amjad Alfaleh
Abdullah Alkattan
Abrar Alzaher
Nashwa Radwan
Nagla Mahmoud
Alaa Alageel
Dina Alhabib
Eman Alsalameen
Khlood Sagor
Alhan Haji
Amal Alfaifi
Khaled Alabdulkareem
Mona Ibrahim
Clinical Drug Investigation, 2022, 42 : 799 - 806
[9] Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
Nemet, Ital
Kliker, Limor
Lustig, Yaniv
Zuckerman, Neta
Erster, Oran
Cohen, Carmit
Kreiss, Yitshak
Alroy-Preis, Sharon
Regev-Yochay, Gili
Mendelson, Ella
Mandelboim, Michal
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05): : 492 - 494
[10] Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
Garcia-Perez, Javier
Gonzalez-Perez, Maria
Castillo de la Osa, Maria
Borobia, Alberto M.
Castano, Luis
Jesus Bertran, Maria
Campins, Magdalena
Portoles, Antonio
Lara, Davis
Bermejo, Mercedes
Conde, Patricia
Hernandez-Gutierrez, Lourdes
Carcas, Antonio
Arana-Arri, Eunate
Tortajada, Marta
Fuentes, Inmaculada
Ascaso, Ana
Teresa Garcia-Morales, Maria
Erick de la Torre-Tarazona, Humberto
Arribas, Jose-Ramon
Imaz-Ayo, Natale
Mellado-Pau, Eugenia
Agusti, Antonia
Perez-Ingidua, Carla
Gomez de la Camara, Agustin
Ochando, Jordi
Belda-Iniesta, Cristobal
Frias, Jesus
Alcami, Jose
Perez-Olmeda, Mayte
ECLINICALMEDICINE, 2022, 50

← 1 2 3 4 5 →